POMICELL

Company Overview

Snapshot

Founded in October 2016 by Boaz Buchandler, POMICELL operates with 1–10 employees. The company has raised $4 million across three funding rounds and secured a grant from the Israel Innovation Authority in January 2019. In January 2022, POMICELL appointed a new Chief Executive Officer.

Business overview

POMICELL develops POMI, an AI SaaS solution designed to enhance R&D processes for researchers in the biomedical field. Its core technology offers capabilities such as automatic disease treatment, big data modeling, automatic mechanism of action, hypothesis creation from literature, and medical record-enhanced mechanism of action deciphering. The company aims to provide advanced digital tools to accelerate research and improve patient understanding within personalized medicine, serving markets in digital healthcare and medical decision support.

Strategic signal

POMICELL ceased operations in June 2024, indicating a significant shift in the company's trajectory. This development signals to investors and innovation teams that the company is no longer an active entity in the Health Tech & Life Sciences sector, prompting a re-evaluation of its market position and potential impact.

Company Intelligence Q&A

What is POMICELL's primary focus?

POMICELL focuses on developing an AI SaaS solution called POMI, which assists biomedical researchers in enhancing R&D processes through AI-driven modeling and analysis for personalized medicine.

When was POMICELL founded and by whom?

POMICELL was founded in October 2016 by Boaz Buchandler.

What is the status of POMICELL?

POMICELL is currently non-active, having ceased operations in June 2024.

What was a key leadership change at POMICELL?

In January 2022, POMICELL appointed a new Chief Executive Officer.

What non-equity funding did POMICELL receive?

In January 2019, POMICELL secured a grant from the Israel Innovation Authority, which was confirmed by Anna Rozen from the company's Data team.